Early phase clinical trials

Current early phase trials in Cambridge

The table below shows the current early phase trials coordinated by the Cambridge Cancer Trials Centre (last updated April 2016). Please download the Early Phase Clinical Trials Team (EPCTT) newsletter for January 2017 to find out the latest news about early phase clinical trials in the Cambridge region.

Trial name Trial description Contact
AZD9496 – Oral SERD Phase I A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9496 in Women with Estrogen Receptor Positive HER-2 Negative Advanced Breast Cancer Dr Richard Baird 
An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients with Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Unresectable Melanoma. An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients with Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Unresectable Melanoma. Dr Pippa Corrie 
CALIBRATE CAmbridge LIquid Biopsy and tumouR profiling study for pATients on Experimental Therapeutics Trials Dr Richard Baird 
CamBMT1 Cambridge Brain Mets Trial 1: A proof-of-principle phase 1b/ randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy Dr Richard Baird 
CAMPLEX To assess the safety of continuous IV administration of the CXCR4 antagonist, plerixafor (MozobilTM), at potentially active plasma concentrations and assess its impact on the immune microenvironment in patients with advanced pancreatic, high grade serous ovarian and colorectal adenocarcinomas Prof Duncan Jodrell
ComPAKT ComPAKT: A Phase I trial of olaparib in combination with AZD5363 Dr Bristi Basu
CaNCaP02 - CAmbridge Neoadjuvant CAncer of the Prostate Study 2 A study into the pharmacodynamic biomarker effects of AZD2014 (an mTOR1/2 inhibitor) given prior to Radical Prostatectomy Dr Simon Pacey
DARPins (MP0250)  A phase I multi-center, open-label, repeated-dose, dose-escalation study to assess safety, tolerability and pharmacokinetics of MP0250 in patients with advanced solid tumors. Dr Richard Baird 
I-BET A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies Dr Brian Huntly
Phase 1 trial of olaparib with temozolomide in relapsed glioblastoma (OPARATIC) A Cancer Research UK Phase I trial of olaparib (AZD2281), an oral PARP Inhibitor, in combination with extended lowdose oral temozolomide in patients with relapsed glioblastoma Dr Sarah Jefferies 
PAKT A  Phase II, randomized, placebo-controlled study of the AKT inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer  Dr Richard Baird 
PiSSARO p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 Dr Bristi Basu
POSIEDON NCRN Phase I/prospective randomised phase II trial Of the Safety and Efficacy of tamoxifen in combination with alpha Isoform selective Pi3K inhibitor GDC-0032 compared with tamoxifen alONe in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment Dr Richard Baird 
RADICAL A randomised phase IIa study (with combination safety run-in) to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole versus exemestane alone in ER positive breast cancer patients who are progressing on current treatment with anastrozole or letrozole Dr Richard Baird 
STAR-PAC An early phase clinical trial of Gemcitabine/Nab-Paclitaxel for pancreatic cancer  Dr Bristi Basu
TAX-TORC A phase 1 multi-centre trial of the combination of AZD2014 (dual mTORC1 and mTORC2 inhibitor) and weekly Paclitaxel in patients with solid tumours Dr Bristi Basu
TRAP - study in subjects with MPM, PM or NSCLC NCRN - 3003: Phase 1 Study in Subjects with Tumors Requiring Arginine to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ADIPemCis) (TRAP Study) Dr Simon Pacey
VanSel1: A Phase I trial of Vandetanib and Selumetinib A Cancer Research UK Phase I dose escalation trial of oral VEGFR and EGFR inhibitor, Vandetanib in combination with the oral MEK inhibitor, Selumetinib (VanSel-1) in solid tumours (dose escalation) and NSCLC (expansion cohort) Dr Simon Pacey

If you would like further information about how to take part in any of the early phase clinical trials listed here, please talk to your cancer specialist as patients usually need to be referred by their doctor. 

Cambridge Cancer Trials Centre contact for early phase trials: Professor Duncan Jodrell